In this study, the authors hypothesized that the observed reduction in lung fibrosis in response to CpG-ODN treatment is due to the increased TLR9 induced Interferon-beta (IFN-β) expression, which was shown to reduce lung fibroblast proliferation. The gene discussed is TLR9; the disease is pulmonary fibrosis.